Free Cash Flow Chart

View Free Cash Flow for IOVA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Free Cash Flow Chart
Start Trial

Historical Free Cash Flow Data

View and export this data back to 2008. Start Trial.
Date Value
June 30, 2026 -296.40M
March 31, 2026 -305.02M
December 31, 2025 -336.24M
September 30, 2025 -351.82M
June 30, 2025 -323.54M
March 31, 2025 -347.50M
December 31, 2024 -364.05M
September 30, 2024 -374.08M
June 30, 2024 -400.48M
March 31, 2024 -405.08M
December 31, 2023 -384.11M
September 30, 2023 -377.30M
June 30, 2023 -354.68M
March 31, 2023 -333.42M
December 31, 2022 -313.18M
September 30, 2022 -293.91M
June 30, 2022 -296.25M
March 31, 2022 -277.66M
December 31, 2021 -265.52M
September 30, 2021 -290.12M
June 30, 2021 -281.11M
March 31, 2021 -259.09M
December 31, 2020 -251.92M
September 30, 2020 -223.15M
June 30, 2020 -208.20M
Date Value
March 31, 2020 -201.82M
December 31, 2019 -165.81M
September 30, 2019 -140.40M
June 30, 2019 -125.38M
March 31, 2019 -114.49M
December 31, 2018 -102.45M
September 30, 2018 -91.51M
June 30, 2018 -84.83M
March 31, 2018 -78.01M
December 31, 2017 -79.74M
September 30, 2017 -71.73M
June 30, 2017 -62.96M
March 31, 2017 -49.24M
December 31, 2016 -34.19M
September 30, 2016 -28.02M
June 30, 2016 -19.00M
March 31, 2016 -19.84M
December 31, 2015 -19.52M
September 30, 2015 -17.53M
June 30, 2015 -15.51M
March 31, 2015 -12.20M
December 31, 2014 -10.23M
September 30, 2014 -7.738M
June 30, 2014 -6.288M
March 31, 2014 -5.646M

Free Cash Flow Range, Past 5 Years

View Free Cash Flow Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Free Cash Flow Benchmarks

View Free Cash Flow Benchmarks
Start Trial
Amgen, Inc. 10.18B
Halozyme Therapeutics, Inc. 806.22M
Neurocrine Biosciences, Inc. 812.00M
AVITA Medical, Inc. -25.21M
Editas Medicine, Inc. -120.55M